Cognitive Research Peptides: Semax and Selank Compared
A comparative research overview of Semax and Selank — two synthetic heptapeptides developed in Russia and studied for neuroprotection, BDNF modulation, anxiolytic effects, and cognitive function in preclinical models.
Shared Origins, Different Targets
Semax and Selank share several structural and developmental characteristics — both are synthetic heptapeptides, both incorporate a Pro-Gly-Pro C-terminal extension for metabolic stability, and both emerged from Russian research institutes in the 1980s–1990s. Both are registered pharmaceuticals in Russia. Despite these similarities, their parent sequences and primary pharmacological targets are distinct: Semax derives from ACTH(4-7) and acts primarily through BDNF upregulation and neuroprotective mechanisms; Selank derives from tuftsin and acts primarily through GABAergic modulation and anxiolytic pathways. This distinction has practical implications for research design.
| Property | Semax | Selank |
|---|---|---|
| Parent peptide | ACTH(4-7) fragment | Tuftsin (immunoglobulin G fragment) |
| Molecular weight | ~874 Da | ~751 Da |
| Primary research focus | Neuroprotection, BDNF/NGF, cognitive function | Anxiolytic effects, GABA-A modulation, stress response |
| Secondary research areas | Dopaminergic/serotonergic modulation | Immunomodulation, cognitive function |
| Registered pharmaceutical | Russia (Pharmsyntez) | Russia and Ukraine (brand: Selank) |
| Research stage | Preclinical + some Russian clinical data | Preclinical + Russian clinical/pharmacological data |
Semax: The BDNF-Upregulation Pathway
The core of Semax research is its effect on brain-derived neurotrophic factor (BDNF) — a neurotrophin essential for neuronal survival, synaptic plasticity, and the long-term potentiation (LTP) associated with memory consolidation.
- BDNF/NGF upregulation: Robust hippocampal mRNA increases — the primary mechanistic signature of Semax
- trkB receptor upregulation: The signaling receptor for BDNF is co-upregulated, potentially amplifying BDNF's downstream effects
- Neuroprotection: Reduced infarct volume and preserved peri-infarct neurons in rodent MCAO stroke models
- Cognitive function: Improved spatial memory in Morris water maze and passive avoidance tests
- Research identity: Best framed as a BDNF-upregulating neuroprotective agent
Selank: The GABAergic Modulation Pathway
Selank's primary mechanistic research context is GABA-A receptor modulation — the same receptor family targeted by classical benzodiazepines, but with a distinct pharmacological profile.
- GABA-A PAM: Enhances chloride conductance at benzodiazepine-sensitive sites without full BZD efficacy
- No sedation in rodent models: Elevated plus maze anxiolytic effect comparable to diazepam without motor impairment
- Tuftsin heritage: Retains immunostimulatory properties from its parent peptide — relevant to neuroimmune research
- Cognitive effects: Improved passive avoidance and working memory — partially attributed to stress-reduction rather than direct nootropic mechanisms
- Research identity: Best framed as a GABA-A partial modulator with neuroimmune properties
Research Comparison: When to Use Each
For researchers choosing between Semax and Selank, the decision should be based on the specific neurobiological pathway under investigation.
| Research Question | Better Fit | Reason |
|---|---|---|
| BDNF pathway activation and measurement | Semax | Direct, robust BDNF/NGF mRNA upregulation is primary mechanism |
| Hippocampal neuroplasticity and LTP | Semax | trkB upregulation + LTP enhancement in hippocampal electrophysiology |
| Ischemic neuroprotection models | Semax | Established MCAO model data; reduced infarct volume |
| GABA-A receptor modulation research | Selank | Allosteric modulation at BZD site; partial agonist profile |
| Anxiety and stress response models | Selank | Elevated plus maze, forced swim; anxiolytic without sedation |
| Neuroimmune interaction research | Selank | Tuftsin-derived immunomodulatory effects; IL-6/TNF-α modulation |
| General cognitive function (both applicable) | Either | Both show memory improvement in different paradigms |
| Combined neuroprotective + anxiolytic | Both (separate arms) | Complementary mechanisms for multi-pathway study design |
Structural and Pharmacokinetic Profile
Both peptides benefit from the same C-terminal Pro-Gly-Pro modification — a tripeptide extension that dramatically slows enzymatic degradation compared to their parent sequences (ACTH(4-7) and tuftsin, respectively). This metabolic stabilization is what enables these compounds to reach and act within the central nervous system rather than being rapidly cleaved by serum peptidases.
| Property | Semax | Selank |
|---|---|---|
| Full sequence | Met-Glu-His-Phe-Pro-Gly-Pro | Thr-Lys-Pro-Arg-Pro-Gly-Pro |
| Residue count | 7 | 7 |
| Molecular weight | ~874 Da | ~751 Da |
| Stability modification | C-terminal Pro-Gly-Pro | C-terminal Pro-Gly-Pro |
| Parent sequence half-life | Minutes (ACTH 4-7 fragments) | Minutes (tuftsin) |
| Storage | Lyophilized: -20°C; Reconstituted: 2–8°C | Lyophilized: -20°C; Reconstituted: 2–8°C |
Quick Reference Summary
- Semax: ACTH(4-7) derivative; primary mechanism is BDNF/NGF upregulation; neuroprotective in ischemia models; cognitive enhancement in rodent spatial memory tasks
- Selank: Tuftsin derivative; primary mechanism is GABA-A positive allosteric modulation; anxiolytic without sedation; immunomodulatory via tuftsin heritage
- Both: Synthetic heptapeptides with C-terminal Pro-Gly-Pro metabolic stabilization; registered pharmaceuticals in Russia
- Research selection: Semax for BDNF/neuroprotection questions; Selank for GABAergic/anxiety questions; both applicable for general cognitive research
- For research use only — not for human consumption